Clinical Trial Details
— Status: Terminated
Administrative data
| NCT number |
NCT04447014 |
| Other study ID # |
200110 |
| Secondary ID |
20-C-0110 |
| Status |
Terminated |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
June 25, 2020 |
| Est. completion date |
January 12, 2023 |
Study information
| Verified date |
January 2023 |
| Source |
National Institutes of Health Clinical Center (CC) |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Background:
Adrenocortical cancer (ACC) is a rare tumor. The prognosis is very poor for people with
advanced stages of ACC. Some people may live with ACC for years; others live for just months.
Treatment options for ACC often do not work well. Researchers want to study the clinical
course of the disease. They want to understand how adrenocortical cancer appear on imaging
scans, how they respond to therapies, and the best treatment for them.
Objective:
To gain a better understanding of adrenal cancer.
Eligibility:
People ages 2 and older with ACC who are enrolled in NCI protocol 19-C-0016
Design:
Participants will be screened with a review of their medical records, tumor scans, and cancer
test results and reports.
Participants may have CT and other scans. For the scans, they will lie in a machine that
takes pictures of the body. They may have blood tests. They may have a 24-hour urine
collection. They may be asked to sign a new consent form for some of these tests.
Participants will complete paper or electronic surveys. The surveys will ask about the
effects of cancer on their emotional, physical, and behavioral well-being.
Participants will receive recommendations about how to manage their issues and potential
treatment options for their cancer.
Participants home physician will be contacted every 6 to 12 months to collect medical
information such as test results and scans.
Participants may be asked to return to the NIH every 6 to 12 months for follow-up tests.
Participants will contact study staff if there are any changes in their tumor.
Participants will be followed on this study for life.
Description:
Background:
- Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million
people per year. It has a very poor prognosis with an overall 5-year mortality rate of
75-90% and an average survival from the time of diagnosis of 14.5 months. Approximately
10% of ACC cases are associated with a hereditary cancer predisposition syndrome.
- The treatment of choice for a localized primary or recurrent tumor is surgical
resection. Patients with recurrent or metastatic disease are infrequently curable by
surgery alone.
- As with most solid tumors, chemotherapy options have limited benefit, although
platinumbased therapies have response rates of 25 to 30%. To date no targeted therapy
has been shown to be of any value in this disease. The role of neoadjuvant and adjuvant
therapies, including systemic chemotherapy and radiotherapy, remains poorly defined and
has been reported to have only a modest or no therapeutic effect.
- The natural history of ACC can vary greatly with some patients surviving only months
while others can live with disease for years. The basis for these differing clinical
presentations is not known. While one cannot exclude an immune or other host component
as responsible for the diverse clinical courses, it is also possible that there may be a
genetic basis for this phenomenon.
- Patients with rare tumors seek expert advice in the management of their care. A natural
history study would establish a more formal mechanism for such referrals, while allowing
the systematic collection of epidemiologic, genomic, molecular data.
Objective:
-Characterize the natural history of adrenocortical cancer (ACC). Data will include patient
demographics, clinical characteristics, patterns of disease progression, response or lack of
response to therapeutic interventions, disease recurrence and overall survival.
Eligibility:
- Subjects with documented ACC
- Age greater than or equal to 2 years old.
Design:
- This protocol is a subprotocol to protocol 19C0016 Natural History and Biospecimen
Accrual Study for Children and Adults with Rare Solid Tumors . After enrollment on the
master protocol and undergoing evaluations detailed in the master protocol, patients
will be enrolled on this subprotocol specific for ACC.
- Medical history will be collected from medical records and patients followed throughout
the course of their illnesses, with particular attention to patterns of disease
recurrence and progression, response to therapies, duration of responses and hormone
production in patients with hormone production as a manifestation of their disease, and
patient reported outcomes. Tumor growth rates will also be calculated throughout the
course of the disease.
